Coherus Oncology, Inc. (CHRS) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for Coherus Oncology, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, Coherus Oncology, Inc.'s filing signal
turned positive.
earningsVibe SuperAnalyst™ Verdict:
TURNED POSITIVE
Signal Performance — Stock Price Since Filing
30-Day Change
-11.92%
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Positive
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does Coherus Oncology, Inc. actually do?
Answer:
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immuno-oncology medicines. Its lead product, LOQTORZI(R) (toripalimab-tpzi), an anti-PD-1 antibody developed with Junshi Biosciences, is approved in the U.S. for nasopharyngeal carcinoma (NPC) and is being evaluated in other cancer types. The company's pipeline includes two mid-stage clinical candidates, casdozokitug (targeting IL-27) and tagmokitug (targeting CCR8), which are being studied in combination with LOQTORZI and other agents. Coherus is also working to onshore its biomanufacturing processes to the United States. The company's strategy centers on growing LOQTORZI sales and advancing its pipeline through clinical studies and strategic partnerships.
Question:
What are Coherus Oncology, Inc.'s revenue drivers?
Answer:
Revenue is primarily driven by sales of LOQTORZI in the United States. The company also generates royalty revenue from licensing agreements.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required